Aaron Wealth Advisors LLC Invests $200,000 in BeOne Medicines Ltd. - Sponsored ADR $ONC

Key Points

• Aaron Wealth Advisors LLC acquired a new stake in BeOne Medicines, purchasing 828 shares valued at approximately $200,000 during the second quarter.
• BeOne Medicines reported earnings per share (EPS) of $0.84 for the last quarter, significantly exceeding estimates of $0.48, while the firm's revenue was $1.32 billion.
• BeOne Medicines has received positive ratings from several analysts, with Barclays initiating coverage and setting a target price of $385.00.

Aaron Wealth Advisors LLC bought a new position in shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 828 shares of the company's stock, valued at approximately $200,000.

Separately, Parallel Advisors LLC acquired a new position in BeOne Medicines during the second quarter worth about $59,000. Institutional investors own 48.55% of the company's stock.

BeOne Medicines Stock Down 2.2%

NASDAQ ONC traded down $7.55 on Tuesday, reaching $330.27. The company had a trading volume of 23,766 shares, compared to its average volume of 420,302. The stock has a market capitalization of $36.22 billion, a P/E ratio of -190.91 and a beta of 0.21. The company's fifty day moving average is $310.42 and its 200 day moving average is $268.97. BeOne Medicines Ltd. - Sponsored ADR has a 52-week low of $170.99 and a 52-week high of $351.27. The company has a quick ratio of 1.72, a current ratio of 1.95 and a debt-to-equity ratio of 0.04.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.36. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%.The business had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.24 billion. Sell-side analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ONC has been the subject of several research analyst reports. Barclays initiated coverage on BeOne Medicines in a research note on Thursday, September 18th. They set an "overweight" rating and a $385.00 target price for the company. Royal Bank Of Canada boosted their target price on BeOne Medicines from $349.00 to $364.00 and gave the stock an "outperform" rating in a research note on Thursday, August 7th. Wall Street Zen downgraded BeOne Medicines from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. JPMorgan Chase & Co. upped their price objective on BeOne Medicines from $321.00 to $345.00 and gave the company an "overweight" rating in a research note on Thursday, July 17th. Finally, Morgan Stanley upped their price objective on BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research note on Friday, June 27th. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average target price of $336.30.

Insider Activity

In other news, CEO John Oyler sold 27,803 shares of the firm's stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $325.71, for a total transaction of $9,055,715.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the firm's stock in a transaction on Friday, September 5th. The shares were sold at an average price of $337.00, for a total value of $898,105.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 181,315 shares of company stock worth $54,839,498. 6.62% of the stock is owned by insiders.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.